within Pharmacolibrary.Drugs.ATC.J;

model J05AH04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.24,
    Cl             = 3.45 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,
    adminCount     = 1,
    Vd             = 0.0485,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Laninamivir is a neuraminidase inhibitor antiviral drug primarily used for the treatment and prophylaxis of influenza A and B. It is currently approved and used in Japan and some other regions but not in the United States or Europe. The drug is known for its long-acting effect, enabling single-dose inhalation therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data based on healthy adult volunteers after single inhaled administration.</p><h4>References</h4><ol><li><p>Toyama, K, et al., &amp; Ishizuka, H (2018). Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects. <i>Antimicrobial agents and chemotherapy</i> 62(1) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01722-17&quot;>10.1128/AAC.01722-17</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29061751/&quot;>https://pubmed.ncbi.nlm.nih.gov/29061751</a></p></li><li><p>Yoshihara, K, et al., &amp; Kubo, Y (2013). Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. <i>Drug metabolism and pharmacokinetics</i> 28(5) 416–426. DOI:<a href=&quot;https://doi.org/10.2133/dmpk.dmpk-12-rg-115&quot;>10.2133/dmpk.dmpk-12-rg-115</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23574886/&quot;>https://pubmed.ncbi.nlm.nih.gov/23574886</a></p></li><li><p>Ikematsu, H, &amp; Kawai, N (2011). Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. <i>Expert review of anti-infective therapy</i> 9(10) 851–857. DOI:<a href=&quot;https://doi.org/10.1586/eri.11.112&quot;>10.1586/eri.11.112</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21973296/&quot;>https://pubmed.ncbi.nlm.nih.gov/21973296</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AH04;
